GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bio-Path Holdings Inc (NAS:BPTH) » Definitions » Total Revenue Growth Rate (Future 3Y To 5Y Est)

Bio-Path Holdings (Bio-Path Holdings) Total Revenue Growth Rate (Future 3Y To 5Y Est) : N/A (As of Jun. 10, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Bio-Path Holdings Total Revenue Growth Rate (Future 3Y To 5Y Est)?

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the average growth rate of total revenue estimates over a 3-year to 5-year period.

As of today, Bio-Path Holdings's Total Revenue Growth Rate (Future 3Y To 5Y Est) is N/A.

Competitive Comparison of Bio-Path Holdings's Total Revenue Growth Rate (Future 3Y To 5Y Est)

For the Biotechnology subindustry, Bio-Path Holdings's Total Revenue Growth Rate (Future 3Y To 5Y Est), along with its competitors' market caps and Total Revenue Growth Rate (Future 3Y To 5Y Est) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bio-Path Holdings's Total Revenue Growth Rate (Future 3Y To 5Y Est) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bio-Path Holdings's Total Revenue Growth Rate (Future 3Y To 5Y Est) distribution charts can be found below:

* The bar in red indicates where Bio-Path Holdings's Total Revenue Growth Rate (Future 3Y To 5Y Est) falls into.


Bio-Path Holdings  (NAS:BPTH) Total Revenue Growth Rate (Future 3Y To 5Y Est) Explanation

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.

In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.

Bio-Path Holdings Total Revenue Growth Rate (Future 3Y To 5Y Est) Related Terms

Thank you for viewing the detailed overview of Bio-Path Holdings's Total Revenue Growth Rate (Future 3Y To 5Y Est) provided by GuruFocus.com. Please click on the following links to see related term pages.

Bio-Path Holdings (Bio-Path Holdings) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bio-Path Holdings Inc (NAS:BPTH) » Definitions » Total Revenue Growth Rate (Future 3Y To 5Y Est)
Comparable Companies
BTAX TOVX CING KTTA ERNA TRVN FREQ CYCC APM LIPO OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
IBPB:Germany
Address
4710 Bellaire Boulevard, Suite 210, Bellaire, TX, USA, 77401
Website
https://www.biopathholdings.com
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's lead drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. Its other drugs are BP1002 and BP1003.
Executives
Aline Sherwood director 347 BRANDYWINE DRIVE, IRWIN PA 15642
Tamaro Martina Molsbergen director 1307 SUMMERHILL DRIVE, MALVERN PA 19355
Mark P Colonnese director 4674 ANDREA POINTE, MARIETTA GA 30062
Peter Henry Nielsen director, officer: President, CEO & CFO 20651 PRINCE CREEK, KATY TX 77450
Paul Aubert director 4710 BELLAIRE BOULEVARD, SUITE 210, BELLAIRE TX 77401
Armistice Capital, Llc 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd. 10 percent owner C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Heath Cleaver director 4010 BALSAM FIR LN., SPRING TX 77386
Ulrich W. Mueller officer: COO & Secretary 17841 6TH AVE NW, SHORELINE WA 98177
Amy Sing director C/O SAETTLE GENETICS INC, 21823 30TH DRIVE SE, BOTHELL WA 98021
Michael J. Garrison director 2626 SOUTH LOOP, SUITE 180, HOUSTON TX 77054
Douglas P Morris director 550 MADISON AVENUE, SUITE 3206, NEW YORK NY 10022
Gillian C Ivers-read director C/O PHARMION CORPORATION, 2525 28TH STREET, BOULDER CO 80301
Thomas E Garrison director P O BOX 150248, OGDEN UT 84415